The FDA has reported adverse event reports that may relate to patients being prescribed compounded semaglutide or tirzepatide in doses beyond the approved labeling, including more product per dose, more frequent dosing, or faster titration, and has told providers to be vigilant
Early detection and treatment are crucial in managing blood clots effectively
If you are fatigued or dizzy, make sure youre getting enough protein and hydrating
Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, JPYC S, Lee MS, Kopetz S , Nixon AB, Bertagnolli MM, Perou CM, Innocenti F